| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -20.45 M USD | -24.67 M USD | -32.02 M USD | -39.03 M USD | -30.26 M USD | -17.70 M USD |
| Depreciation & Amortization | 122000 USD | 551000 USD | 571000 USD | 614000 USD | 685000 USD | 209000 USD |
| Stock-Based Compensation | 1.27 M USD | 3.13 M USD | 4.45 M USD | 5.81 M USD | 5.66 M USD | 1.49 M USD |
| Capital Expenditures | 16000 USD | 146000 USD | 180000 USD | 321000 USD | 2.03 M USD | 1.21 M USD |
| Cash Flow from Investing | 19.77 M USD | 22.44 M USD | 38.41 M USD | 49.95 M USD | -143.12 M USD | -1.40 M USD |
| Cash Flow from Financing | -645000 USD | -787000 USD | -11.17 M USD | -287000 USD | 163.94 M USD | 35.45 M USD |
| Dividends Paid | — | — | — | — | — | — |
| Stock Buybacks | — | — | 10.38 M USD | — | — | — |
| Free Cash Flow | -20.47 M USD | -24.82 M USD | -32.20 M USD | -39.35 M USD | -32.28 M USD | -18.91 M USD |
Sensei Biotherapeutics Inc is a cutting-edge biotechnology company focused on developing novel immunotherapies to treat cancer. Primarily, the company aims to harness the power of the immune system to target and eliminate cancerous cells, leveraging breakthroughs in scientific research and molecular biology. Sensei Biotherapeutics operates in the burgeoning field of oncology, which remains a critical area of medical research due to the global impact of cancer. The company's proprietary platform technology is designed to generate highly specific and potent therapeutic agents that could potentially improve patient outcomes in various cancer types. By innovating within the field of cancer immunotherapy, Sensei Biotherapeutics serves a significant role in the pharmaceutical and biotechnology sectors, contributing to the development of next-generation treatment modalities. The company’s R&D efforts are instrumental in advancing therapeutic strategies that are shaping the future of personalized cancer care and increasing the potential for successful interventions across diverse patient populations.